Edwards Lifesciences reported second-quarter 2026 net sales of $1.741 billion and adjusted diluted EPS of $0.78, with GAAP diluted EPS of $0.42. Gross profit margin was 77.5% and operating income from continuing operations was $513.2 million for the quarter. The company raised its 2026 sales growth guidance to 10%–11%, increased TAVR and TMTT guidance, and reaffirmed adjusted EPS guidance of $2.95–$3.05.

Financial Highlights

  • Revenue (Net sales) — $1,741.0 million for the three months ended June 30, 2026.
  • Gross profit — $1,348.6 million; gross profit margin 77.5% (77.6% adjusted).
  • Operating income — $513.2 million for the quarter (29.5% of sales).
  • Net income attributable to Edwards Lifesciences — $241.9 million for the quarter; diluted GAAP EPS $0.42.
  • Adjusted diluted EPS — $0.78 for the quarter; reaffirmed full-year adjusted EPS guidance of $2.95 to $3.05.

Business Highlights

  • TAVR momentum — TAVR product group sales of $1,258.3 million in Q2, up 11.3% year-over-year (10.5% constant currency); adoption noted across U.S., Europe and Japan with stable average selling prices.
  • TMTT growth — Transcatheter mitral and tricuspid therapies sales of $195.9 million (reported $198.6 million adjusted), up 47.3% year-over-year (44.8% constant currency); driven by PASCAL, EVOQUE and SAPIEN M3 adoption.
  • Surgical portfolio traction — Surgical sales of $284.1 million, reflecting continued adoption of RESILIA tissue therapies (INSPIRIS, MITRIS, KONECT) and recent COMMENCE 10-year durability data presented at AATS.
  • Regulatory and clinical milestones — Company expects CLASP II TR and PROGRESS presentations at TCT and anticipates U.S. and European approvals/launches for next-generation PASCAL and U.S. tricuspid PASCAL in Q4.
  • Capital allocation and liquidity — Cash and cash equivalents of approximately $2.9 billion, total debt about $600 million, and roughly $1.5 billion remaining under share repurchase authorization.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.